Expanded access use of MRTX849 for the treatment of patients with advanced solid tumors with a KRAS G12C mutation
Clinical Trial Grant
Awarded By
Mirati Therapeutics, Inc.
Start Date
August 12, 2022
End Date
February 9, 2024
Awarded By
Mirati Therapeutics, Inc.
Start Date
August 12, 2022
End Date
February 9, 2024